SAN DIEGO, Aug. 2 /PRNewswire/ -- Novalar Pharmaceuticals, Inc., a specialty pharmaceutical company focused in dental, today announced that OraVerse®, the company's premier pharmaceutical product, has again been selected by leading dental industry magazine Dentistry Today as one of its 'Top 100 Products' for 2010. The full results of the 24th annual competition were published in the July issue.
OraVerse is the first and only local anesthesia reversal agent that accelerates the return to normal sensation and function for patients who want to avoid the unwanted and unnecessary lingering soft tissue anesthesia following routine dental procedures. The first-in-class product is currently available to dentists directly from Novalar.
"Since launch, OraVerse has performed remarkably well in numerous independent product assessments, evaluations and surveys with both dentists and patients," said Donna Janson, President & CEO of Novalar. "We are extremely proud that the readers of Dentistry Today have selected OraVerse for this distinction two years in a row. It is truly a breakthrough dental product."
The 'Top 100 Products' list has honored new and innovative dental products for 24 years. Products included on the list are selected on the basis of reader response. Clinical data for OraVerse has also been published in a number of leading peer reviewed scientific journals including the nation's leading dental publication, the Journal of the American Dental Association.
OraVerse is a breakthrough that reverses unwanted lingering numbness after routine dental procedures where a local anesthetic